Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

Figure 6

Effect of treatment cessation on tumor growth. A, An equal amount of 786-0 cells were injected subcutaneously into nude mice. Once the tumor reached 25 mm3 mice were randomized into four groups and treatments were started with vehicle (Control), NVP-BEZ235 (NVP, 30 mg/kg/day po), Sorafenib (Soraf, 15 mg/kg/day po), or a combination of both (NVP+Soraf). After 10 days, treatments were stopped and tumor growth was further monitored. Points, mean value of tumor volume; bars, SD. Five mice were analyzed in each group. B, Relative tumor volumes (normalized to their size at day 5 off-treatment) at day 10 off-treatment. *, P < 0.05 compared to control.

Back to article page